Wegovy weight loss results "very encouraging," says Novo EVP

Recently launched weight loss drug Wegovy has reportedly shown an average loss of weight of 15.2 percent over two years in a phase IIIb trial. This is "very encouraging," says EVP Martin Holst Lange.

Photo: Tidsvilde Stine/Ritzau Scanpix

An average weight loss of 15.2 percent over two years. These results come from a phase IIIb study of the obesity drug Wegovy, Novo Nordisk reports in a press release in connection with this year's Obesity Week.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs